Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04889105
Other study ID # E3546-W
Secondary ID IK2RX003546-02
Status Recruiting
Phase N/A
First received
Last updated
Start date December 1, 2021
Est. completion date September 30, 2026

Study information

Verified date October 2023
Source VA Office of Research and Development
Contact Arash Harzand, MD
Phone (404) 321-6111
Email Arash.Harzand@va.gov
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Peripheral artery disease (PAD) is a highly prevalent condition affecting up to 10% of Veterans that leads to loss of walking ability and increased risk of amputation. Veterans have limited access to supervised exercise therapy, a facility-based program proven to improve walking ability in PAD, which is poorly attended due to the inconvenience and cost of attending a 12-week program with multiple weekly sessions. This CDA-2 application will investigate the feasibility of home-based exercise therapy (HBET) delivered using mobile health (mHealth) technologies in Veterans with symptomatic PAD. We will partner with the MOVE! program to deliver HBET through group behavioral coaching and a novel wearable activity monitor in a newly proposed program called Smart MOVE!. There is a clear need to provide effective and convenient alternatives to supervised exercise for Veterans with PAD. This study will provide evidence to proceed with Smart MOVE!, a much-needed patient-centered rehabilitation program for Veterans with PAD.


Description:

An estimated 8.5 million Americans (or 7% of US adults) and nearly 10% of veterans are estimated to have peripheral arterial disease (PAD). Significantly debilitating and negatively impacting quality of life, the primary symptom of PAD is claudication (reproducible leg pain with ambulation) that leads to impaired mobility, loss of functional independence, and a heightened risk for amputation. Veterans are at an increased risk of developing symptomatic PAD due to their disproportionately high rates of PAD risk factors such as diabetes, smoking, and hypertension, the most prominent PAD risk factors. Supervised exercise therapy is proven to decrease claudication and enhance mobility in PAD; however, fewer than 25% of eligible patients enroll. Participation in this facility-based program requires travel to a rehabilitation center 3 times per week for 12-weeks, which can be burdensome and costly for Veterans, many of whom live in rural areas and on fixed incomes. There is, therefore, a need to develop a convenient and effective alternative exercise rehabilitation program for Veterans with PAD, particularly in light of safety considerations now associated with this population's travel to group facilities in the current COVID pandemic. A promising approach to increase access to exercise rehabilitation for PAD is remote, home-based exercise therapy (HBET). HBET programs combine self-led walking exercises with health coaching and exercise tracking with a wearable activity monitor. Adapting HBET to PAD is difficult, however, due to the added complexity of an exercise prescription that requires the patient to walk until they experience near-maximal leg pain. Even with active coaching, successfully implementing HBET for PAD with long-term adherence has been difficult in the past. The goal is of this study is to leverage newer mobile health (mHealth) tools to adapt HBET for PAD. This technology-enhanced approach for HBET will be conducted by partnering with a successful VA lifestyle program, MOVE!, which has demonstrated success in achieving sustained weight loss and reduced diabetes onset through lifestyle modification. As increased physical activity is a core element of MOVE!, participation may help increase adherence with HBET for PAD. This newly proposed program, Smart MOVE!, will be a multi-component program featuring a tailored version of MOVE! and a novel mHealth device to improve convenience, access, and adherence to HBET for PAD.


Recruitment information / eligibility

Status Recruiting
Enrollment 75
Est. completion date September 30, 2026
Est. primary completion date March 31, 2026
Accepts healthy volunteers No
Gender All
Age group 40 Years and older
Eligibility Inclusion Criteria: - Age >40 years - Eligible Veteran status - Clinically stable intermittent claudication ( 2 months of Rutherford Class II symptoms, no evidence of chronic limb-threatening ischemia) - Established PAD diagnosis (abnormal ankle-brachial index or evidence of PAD on prior certified vascular laboratory or radiology imaging) - Access to safe location to perform walking exercises Exclusion Criteria: - Above or below knee amputation - critical limb ischemia (rest pain or tissue loss including ulceration or gangrene) - inability to walk without a walker - wheelchair confinement - non-English speaking - significant visual impairment that interferes with walking activity - hearing impairment that interferes with full study participation - unable or unwilling to return to the medical center at the expected visit frequency or unable or unwilling to use the technology required for the intervention - Individuals whose walking is limited by a condition other than PAD - Any active cardiac condition including unstable angina - unstable atrial or ventricular arrhythmias - high-grade heart block without a pacemaker - active myopericarditis - recent venous thromboembolism - or recent abnormal baseline stress test suggesting ischemia - other high-risk findings (e.g., drop of systolic blood > 20 mmHg with exercise) - Presence of Class III NYHA heart failure or CCS III angina. - Major surgery including lower extremity revascularization or orthopedic surgery during the preceding three months or anticipated in the next nine months - Major medical illness including lung disease requiring continuous oxygen (patients wearing nighttime oxygen only may still qualify) - neurodegenerative disorders such as Parkinson's Disease that impair walking ability - cancer requiring treatment in the past 2 years (with exception for non-melanoma skin cancer or if they received treatment for early-stage cancer with an excellent overall prognosis) - Heart attack, stroke, or coronary artery bypass surgery in the preceding 3 months - Mental health illness that may interfere with the ability to consent and/or participate in the study, including mini-mental status examination score <24 - dementia - active psychiatric disorder such as schizophrenia or bipolar disorder - history of suicidal or homicidal ideation in the preceding six months - history of suicidal attempts in the preceding 12 months - history of active substance use in the preceding six months that would interfere with study participation (as determined by their primary care or mental health provider) - Subjects endorsing SI or HI may be eligible for continued participation with monitoring if approved by their primary mental health provider - Currently walking regularly for exercise at a level comparable to the amount of exercise prescribed in the intervention - Currently enrolled in another clinical trial or structured exercise program (i.e., cardiac rehabilitation) - Deemed to be poorly suited for the study or the study intervention at the discretion of the PI or study staff

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Smart MOVE!
Multi-component behavioral intervention of PAD consisting of: guideline-directed HBET prescription active behavioral coaching (via MOVE! program or other) mobile health monitoring
General walking advice
Basic guidance on performing walking exercises for PAD according to established guidelines. Participants will receive a mobile health device for self-tracking only but not receive any behavioral coaching.
Performance evaluation
Preliminary performance evaluation determine the optimal components of the Smart MOVE! intervention. Specific procedures will include: Provider and stakeholder interviews PAD patient interviews 2) N-of-1 trials to refine the intervention

Locations

Country Name City State
United States Atlanta VA Medical and Rehab Center, Decatur, GA Decatur Georgia

Sponsors (2)

Lead Sponsor Collaborator
VA Office of Research and Development LifeQ

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary 6-minute walk test The 6MWT is a well-validated measure of functional capacity and increasingly recognized as a meaningful outcome measure in PAD. Participants will be asked to walk back and forth along a 100-foot hallway for six minutes using standard methods and have their total distance recorded 90 days
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05712395 - The Effects of a Novel, Non-ischemic and Pain-free Exercise Intervention in Peripheral Artery Disease N/A
Active, not recruiting NCT04534257 - Prospective Registry to Investigate the Safety and Efficacy of the Treatment With the Selution Sirolimus Drug Coated Balloon in TASC C and D Atheroma-occlusive Infra-Inguinal Disease in Patients With Chronic Limb Threatening Ischemia From Singapore N/A
Recruiting NCT04511234 - Sirolimus Coated Balloon Versus Standard Balloon for SFA and Popliteal Artery Disease N/A
Recruiting NCT03506633 - Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients N/A
Active, not recruiting NCT03506646 - Dietary Nitrate Supplementation and Thermoregulation N/A
Completed NCT02554266 - Registry Investigating the Clinical Use and Safety of the Lutonix Drug Coated Balloon for Treatment of BTK Arteries
Completed NCT03921905 - Peripheral Artery Disease in Patients With Stable Coronary Artery Disease in General Practice: Prevalence, Management and Clinical Outcomes.
Not yet recruiting NCT06369350 - Vitamin B6 on Exercise Pressor Reflex on Leg Ischemia-reperfusion Early Phase 1
Recruiting NCT04545268 - Prehabilitation for Cardiac Surgery in Patients With Reduced Exercise Tolerance N/A
Recruiting NCT02389023 - Comparison of Prevena Negative Pressure Incision Management System vs. Standard Dressing After Vascular Surgery N/A
Completed NCT02522884 - Tack Optimized Balloon Angioplasty Study of the Tack Endovascular Systemâ„¢ in Femoropoliteal Arteries N/A
Completed NCT02539940 - Elutax-SV Drug-eluting Balloons for Below-the-knee Treatment
Completed NCT02563535 - Evaluation of the Use of ACOTEC Drug-Eluting Balloon Litos ® in Below-The-Knee Arteries to Treat Critical Limb Ischemia Phase 4
Completed NCT02542267 - In-Stent Restenosis Post-Approval Study N/A
Completed NCT02262949 - A Prospective Study of the Bard® LifeStent® Solo Vascular Stent System N/A
Completed NCT02145065 - First-in-man Evaluation of a Novel, Microcrystalline Paclitaxel Coated Balloon for Treatment of Femoropopliteal Artery Disease (PAX-r) N/A
Completed NCT02228564 - BARD® Study of LIFESTREAMâ„¢ Balloon Expandable Covered Stent Treating Iliac Arterial Occlusive Disease N/A
Completed NCT01743872 - Optical Imaging Measurement of Intravascular Solution Efficacy Trial N/A
Recruiting NCT01424020 - Walking Estimated Limitation Calculated by History - Study 2 Phase 4
Active, not recruiting NCT01597453 - NOR-SYS: The Norwegian Stroke in the Young Study N/A